Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.
Yamaguchi A, Ishitobi M, Nagura N, Shimo A, Seki H, Ogiya A, Sakurai T, Seto Y, Oshiro C, Sasada S, Kato M, Kawate T, Kondo N, Narui K, Nakagawa T, Nogi H, Yamauchi C, Tsugawa K, Kajiura Y, Shien T. Yamaguchi A, et al. Among authors: oshiro c. Ann Surg Oncol. 2023 Mar;30(3):1678-1686. doi: 10.1245/s10434-022-12760-1. Epub 2022 Nov 13. Ann Surg Oncol. 2023. PMID: 36371582
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Futamura M, Nakayama T, Yoshinami T, Oshiro C, Ishihara M, Morita M, Watanabe A, Tanigichi A, Tsukabe M, Shimoda M, Nitta K, Chihara Y, Yasojima H, Ouchi Y, Tokumaru Y, Masuda N. Futamura M, et al. Among authors: oshiro c. Breast Cancer. 2023 Nov;30(6):943-951. doi: 10.1007/s12282-023-01485-y. Epub 2023 Jul 24. Breast Cancer. 2023. PMID: 37486454 Free PMC article.
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Yoshinami T, et al. Among authors: oshiro c. Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575-5. Online ahead of print. Breast Cancer. 2024. PMID: 38642245
80 results